Share This

Public company info - Suzhou Basecare Medical Corporation Limited-H Shares , 02170.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Suzhou Basecare Medical Corporation Limited-H Shares, 02170.HK - Company Profile
Chairman LIANG Bo
Share Issued (share) 81,000,000
Par Currency Renminbi
Par Value 1.0
Industry Biotechnology
Corporate Profile Business Summary: The group is an innovative platform of genetic testing solutions for assisted reproduction in China. Performance for the year: For the years ended December 31, 2018 and 2019 and the nine months ended September 30, 2019 and 2020, the group’s revenues generated from NIPT kits, MGD kits and testing devices and instruments were RMB18.3 million, RMB23.6 million, RMB18.1 million and RMB30.6 million, respectively, representing 56.0%, 42.3%, 43.3% and 53.3% of the group’s total revenue, respectively. Business Review The group is an innovative platform of genetic testing solutions for assisted reproduction in China, according to Frost & Sullivan. the group’s PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA, compare to other PGT-A products based on fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (qPCR) technologies. The NMPA registration of the group’s PGT-A kit, in February 2020, as a Class III “innovative medical device,” marked the birth of a regulated third-generation IVF market in China in which The group is, to date, the only approved kit maker. There are other PGT-A kits in China that are in the process of applying for the NMPA registration certificate and sold for limited scientific research purposes. The group is developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR kits, which, together with the group’s PGT-A kit, would form a complete test kit lineup to occupy the PGT field, all based on next-generation sequencing, or NGS, technologies. the group expect to obtain NMPA registration approval for these kits in 2022 and 2024, respectively, which the group anticipate would further the group’s dominance in the third-generation IVF genetic test kit market in China, well ahead of potential competition. Leveraging the group’s core strength in PGT, the group have positioned ourselves to become an innovative platform in China’s broader reproductive genetics market. the group have extended the group’s reach beyond the pre-implantation stage to the prenatal and postnatal stages, and are developing one kit in each stage, which makes us a company in China with a genetic test kit pipeline that covers the full reproductive cycle, according to Frost & Sullivan. Beyond test kits, the group have developed a number of innovative devices and instruments that can improve work flow in molecular genetic laboratories with the group’s kits. In addition to the group’s self-developed products, the group also distribute DA8600, the only NGS sequencer approved by the NMPA for PGT, on which the group’s test kits are designed to run, and a number of other test kits. The group have pioneered a solution model under which the group provide the group’s clients, which are hospitals and reproductive clinics in China offering the relevant assisted reproductive services, with one-stop, customized integrated solutions, including not only consumables (test kits) and hardware devices and instruments but also comprehensive services, such as providing guidance and advice on laboratory design, operation and management, pre-sale and after-sale technical support, on demand based on specific individual needs, to help them establish from scratch, and further enhance, their reproductive genetic testing, analysis and counseling capabilities. Through the group’s comprehensive solutions, the group aspire to empower the group’s clients to better serve reproductive patients in China in ways that did not exist before. Third-generation IVF is only beginning to develop in China. The large population base, growing awareness and acceptance of PGT as part of IVF treatments, and a PGT penetration rate that is significantly lower than that in the United States suggest significant growth potential. Based on the group’s dominant leadership in PGT, the group believe The group is strategically positioned to serve the larger reproductive genetics medical devices market. The group have strong R&D capabilities based on a clinically driven R&D model to develop one-stop, customized integrated reproductive genetics solutions to address unmet clinical needs in China, tailored to overcome the challenges specific to the Chinese patient population. the group focus on developing intellectual property—a combination of patents, copyrights, proprietary know-how and trade secrets—for products and solutions that the group believe have mass-market demand potential and clear regulatory pathway visibility. In addition to conducting internal R&D programs, the group partner with key business partners in many aspects of the group’s business, such as major hospitals and reproductive clinics in China, global life sciences and biotechnology companies in the industry, such as Thermo Fisher, and academic institutions, such as the Chinese University of Hong Kong. the group maintain solid relationships with influential KOLs and physicians in the assisted reproduction medical field and establish joint laboratories with major hospitals and reproductive clinics in China, so that the group understand the most acute needs of frontline clinical care. the group believe the group’s holistic R&D approach and comprehensive capabilities have been the foundation of the group’s industry position. The group have a dedicated management team with deep industry experience and firm commitment to the reproductive genetics cause, led by the group’s founder and chairman of the Board, Dr. Liang. With over ten years of experience in bioinformatics, Dr. Liang has not only led the development of successful products and technologies in the genetic testing field, but also enjoyed a good reputation in the academic community, having co-published over 20 academic papers in respected scientific journals. the group’s R&D team has a stable core of industry veterans, including Dr. Liang, who have worked together in the reproductive science industry for almost a decade. Prospects: The group intend to implement the following business strategies: (i) continue to capture and solidify sales channels and customer base for PGT-A; (ii) rapidly commercialize product portfolio to occupy full reproductive cycle; (iii) develop next-generation automated and intelligent hardware to upgrade industry infrastructure; and (iv) maintain technological leadership by leveraging advancements of global leaders.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.